VBI 1501A

Drug Profile

VBI 1501A

Alternative Names: VBI-1501A

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator Epixis; VBI Vaccines
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 20 Sep 2016 VBI Vaccines completes enrolment in a phase I trial in Cytomegalovirus infections (Prevention) in Canada , NCT02826798)
  • 23 Jun 2016 Phase-I clinical trials in Cytomegalovirus infections (Prevention) in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top